Con: Treating hepatitis C virus With direct‐acting antivirals: Fear not the perceived threat of hepatocellular carcinoma

Mehta, Neil; Yao, Francis Y.

doi:10.1002/lt.24959

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This issue remains a topic of debate, leading to uncertainty if or when to treat HCV‐infected patients with a history of HCC . These data have created fear among patients receiving DAA therapy and prompted some providers to withhold HCV treatment from patients with a history of HCC.…”

Section: Introductionmentioning

confidence: 99%

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Saraiya

Yopp

Rich

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Saraiya

Yopp

Rich

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In contrast, other studies have shown long‐term clinical benefits of DAA treatment, including decreased risk for HCC, lower risk of decompensation and a reduction in liver‐related mortality 15‐18 . As a result, there have been different opinions about DAA treatment in relation to the risk for HCC and it has been proposed that further studies of safety are required 19‐21 …”

Section: Introductionmentioning

confidence: 99%

“…[15][16][17][18] As a result, there have been different opinions about DAA treatment in relation to the risk for HCC and it has been proposed that further studies of safety are required. [19][20][21] The immunological changes caused by DAAs and a possibly decreased tumour control have raised a question about the risk for EHC in relation to DAA treatment. 21 A recent study by Kim et al, demonstrated an increased mortality from EHC in the DAA era in a large population cohort, but HCV treatment data were lacking in that study.…”

Section: Introductionmentioning

confidence: 99%

Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct‐acting antivirals

et al. 2021

View full text Add to dashboard Cite

Summary Background and aims Direct‐acting antivirals (DAAs) against HCV have an immune modulatory effect, this could possibly lead to a decreased tumour control. We, therefore, aimed to assess the risk of extrahepatic cancer (EHC) during and the first years after DAA treatment. Methods and Results This is a nationwide cohort study with prospectively collected data for 19 685 persons with HCV, 4013 DAA treated, 3071 interferon (IFN) treated and 12 601 untreated, from 2008 to 2016. Follow‐up time was maximum 3 years. The risk for EHC was compared between the groups using Cox regression analyses, with adjustment for age and Charlson Comorbidity Index (CCI). The HCV‐infected groups were also compared with matched cohorts without HCV from the general population. In total 341 EHCs were identified, 84, 43 and 214 EHC in the DAA, IFN and untreated group respectively. The EHC risk in DAA treated compared with IFN treated was doubled, but when adjusted for age and CCI the HR was 1.07 (95% CI 0.74‐1.56). Compared with the general population, the HR of EHC for the DAA group was 1.45 (CI 1.13‐1.86), with the difference remaining statistically significant after adjusting for CCI. Conclusion We found no increased risk for EHC associated with DAA therapy after adjustment for age and CCI. An increased risk of EHC in DAA treated compared with the general population was though seen, and attention should be paid to this association in the ageing population with a history of HCV infection.

show abstract

Hepatitis C virus associated hepatocellular carcinoma

Khatun

Ray

2021

Advances in Cancer Research

View full text Add to dashboard Cite

Con: Treating hepatitis C virus With direct‐acting antivirals: Fear not the perceived threat of hepatocellular carcinoma

Cited by 4 publications

References 28 publications

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct‐acting antivirals

Hepatitis C virus associated hepatocellular carcinoma

Contact Info

Product

Resources

About